About this trial
Sodium (Na+) hemostasis is abnormal in CKD patients, and this element can be deposited in the skin, muscle, and skeleton - to cope with long term sodium loading. It is known that sodium stored in this non-osmotically active way, is profoundly inflammatory. Furthermore, inflammation has been associated with several uremic symptoms. The investigators will use novel Na+ MRI imaging to examine the Na+ deposition in the skin, muscle, and skeleton of five groups:1) chronic in-center hemodialysis patients, 2) chronic peritoneal dialysis patients, 3) adult and paediatric patients with CKD stage 1-5 and 4) heart failure patients with and without renal dysfunction 5) sex and age-matched healthy adult and paediatric controls. Additionally, they will investigate the association between sodium deposition in these tissues with uremic symptomatology and biochemical markers of metabolism.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age greater than or equal to 6 years
For patients on maintenance hemodialysis or peritoneal dialysis: more than 3 months duration of therapy
For patients with CKD stage 1-5: CKD stage 1-5 and no indications to start dialysis
For heart failure patients: with or without renal dysfunction
Disqualifiers
Pregnant, breastfeeding or intending pregnancy
Unable to give consent or understand written information
Contraindication to MRI study
Trial population
We will recruit up to 400 participants; approximately 125 dialysis patients including 50 children/adolescents on dialysis, 200 patients with various stages of chronic kidney disease including heart failure patients and approximately 25 children/adolescents with chronic kidney disease, and 75 individuals with no kidney disease including approximately 25 healthy children/adolescents.
Trial design
Cohort
Prospective
Treatments tested in this trial
Measuring sodium content
Other interventionSodium MRI measurement of sodium content in the tissues of all participants
Treatment groups
Trial outcomes
Primary outcomes
Na content in the skin, muscle and skeleton of five cohorts
Secondary outcomes
Inflammatory Marker: CRP levels
Uremic symptom scores among the different groups
Liver function markers
Liver damage markers (liver enzymes)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Chris McIntyre
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor institution